Company Analysis
Sign in

Tao Synergies Inc. (TAOX)

Nasdaq: TAOX · Finance Services · New York, NY · filing with the SEC since 2013
Full chart Alerts Compare
Grade4.8
◀ Past 6.2● Present 2.8▶ Future 5.4
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

7 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Tao Synergies Inc.’s names, not what it holds today.

Patents granted
7
7 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and 2 in 2023
Applications published
18
1 of them in 2025
Names they are printed under
4
a former name
By yearGrantedApplications published
'15'17'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Synaptogenix, Inc. a former name
US, as the owner printed on each patent
6 granted
11 published
Neurotrope BioScience, Inc. a former name
named as the applicant on its applications, in US
0 granted
5 published
NEUROTROPE BIOSCIENCE, INC. a former name
US, as the owner printed on each patent
1 granted
1 published
Synaptogenix, Inc. a former name
named as the applicant on its applications, in US
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jun 25, 202412,016,837Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseasesPharmaceuticalsSynaptogenix, Inc.
Nov 28, 202311,826,345Dosing regimens of PKC activatorsPharmaceuticalsSynaptogenix, Inc.
Nov 21, 202311,820,745PKC-activating compounds for the treatment of neurodegenerative diseasesPharmaceuticalsSynaptogenix, Inc.
Jul 19, 202211,390,596PKC-activating compounds for the treatment of neurodegenerative diseasesPharmaceuticalsSynaptogenix, Inc.
Mar 15, 202211,273,139Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseasesPharmaceuticalsSynaptogenix, Inc.
Jun 29, 202111,045,447Methods for inducing synaptogenesis with synaptic growth factor activating compoundsPharmaceuticalsSynaptogenix, Inc.
Aug 8, 20179,724,328Methods and compositions for treatment of lipid storage disordersPharmaceuticalsNEUROTROPE BIOSCIENCE, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Feb 27, 20252025/0064776TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING PKC ACTIVATORSPharmaceuticalsSynaptogenix, Inc.
Dec 12, 20242024/0408056METHODS FOR REPAIRING NERVE DAMAGE USING PKC ACTIVATING THERAPEUTIC AGENTSPharmaceuticalsSynaptogenix, Inc.
Nov 28, 20242024/0390324METHODS OF TREATING AND PREVENTING NEURODEGENERATIVE DISEASES WITH HGF ACTIVATING COMPOUNDSPharmaceuticalsSynaptogenix, Inc.
Jun 6, 20242024/0180869TREATMENT OF MULTIPLE SCLEROSIS USING PKC ACTIVATORSPharmaceuticalsSynaptogenix, Inc.
May 23, 20242024/0165075TREATMENT OF OPTIC NERVE INFLAMMATION USING PKC ACTIVATORSPharmaceuticalsSynaptogenix, Inc.
Jan 25, 20242024/0025870PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASESPharmaceuticalsSynaptogenix, Inc.
Jan 5, 20232023/0000943METHOD OF INDUCING SYNAPTOGENESIS BY ADMINISTERING ANGIOTENSIN AND ANALOGUES THEREOFPharmaceuticalsSynaptogenix, Inc.
Nov 10, 20222022/0356161PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASESPharmaceuticalsSynaptogenix, Inc. · patent 11,820,745 granted from it
Jun 16, 20222022/0184028TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING PKC ACTIVATORSPharmaceuticalsSynaptogenix, Inc.
May 19, 20222022/0151973HALOGENATED ESTERS OF CYCLOPROPANATED UNSATURATED FATTY ACIDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASESPharmaceuticalsSynaptogenix, Inc. · patent 12,016,837 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 6.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton TAOX · research, not advice